


## CLAIMS

## 1. A compound of formula (I):



5

wherein

A and B represent the groups  $-(CH_2)_m-$  and  $-(CH_2)_n-$  respectively;R<sup>1</sup> represents C<sub>1-6</sub>alkyl;10 R<sup>2</sup> represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC<sub>1-6</sub>alkyl, trifluoromethyl, trifluoromethoxy, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy,  $-(CH_2)_pC_{3-6}$ cycloalkyl,  $-(CH_2)_pOC_{3-6}$ cycloalkyl, -COC<sub>1-6</sub>alkyl, -SO<sub>2</sub>C<sub>1-6</sub>alkyl, -SOC<sub>1-6</sub>alkyl, -S-C<sub>1-6</sub>alkyl, -CO<sub>2</sub>C<sub>1-6</sub>alkyl, -CO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, -SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>,  $-(CH_2)_pNR^4R^5$ ,  $-(CH_2)_pNR^4COR^5$ , an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted heterocyclyl group;15 R<sup>3</sup> represents hydrogen or C<sub>1-6</sub>alkyl;Ar<sup>1</sup> represents an optionally substituted heteroaryl group;16 Ar<sup>2</sup> represents an optionally substituted phenyl or an optionally substituted heteroaryl group;Y represents a bond, -O-, -C<sub>1-6</sub>alkyl-, -CR<sup>6</sup>R<sup>7</sup>X-, -XCR<sup>6</sup>R<sup>7</sup>-, -NR<sup>8</sup>CO- or -CONR<sup>8</sup>-;20 X represents oxygen, sulfur, -SO- or -SO<sub>2</sub>-;R<sup>4</sup> and R<sup>5</sup> each independently represent hydrogen or C<sub>1-6</sub>alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring;R<sup>6</sup> and R<sup>7</sup> each independently represent hydrogen, C<sub>1-6</sub>alkyl or fluoro;25 R<sup>8</sup> represents hydrogen or C<sub>1-6</sub>alkyl;

m and n independently represent an integer selected from 1 and 2;

p independently represents an integer selected from 0, 1, 2 and 3;

or a pharmaceutically acceptable salt, solvate or pharmaceutically acceptable derivative thereof.

30

## 2. A compound of formula (I) which is

5-(4-Chlorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amide;

35 5-(3-Methoxyphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amide;

5-(4-Methoxyphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amide;

5-(3,4-Difluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amide;

5-(2,4-Difluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(3-Chlorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(3-Fluorophenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(4-Trifluoromethylphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(3-Trifluoromethylphenyl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(4-Fluorophenyl)-thiophene-2-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(4-Chlorophenyl)-thiophene-2-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)amide;

5-(4-Chloro-2-methylphenyl)-thiophene-2-sulfonic acid (2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;

5-Isoxazol-3-yl-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;

5-(2-Methylthiazol-5-yl)-thiophene-2-sulfonic acid (8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;

[2,3']Bithiophenyl-5-sulfonic acid (2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;

[2,3']Bithiophenyl-5-sulfonic acid (3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yl)-amide;

5-(4-Chlorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)amide;

5-(4-Fluorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)amide;

5-(2,4-Difluorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)amide; and

5-(3,4-Difluorophenyl)thiophene-2-sulfonic acid (8-dimethylamino-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)amide.

35 3. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier therefor.

40 4. Use of a compound of formula (I) according to claim 1 or claim 2 or a pharmaceutically acceptable derivative thereof in therapy.

45 5. Use of a compound of formula (I) according to claim 1 or claim 2 for the treatment of a condition which requires modulation of a dopamine receptor.

6. Use of a compound of formula (I) according to claim 5 wherein the condition is schizophrenia or substance abuse.

5 7. Use of a compound of formula (I) according to claim 1 or claim 2 in the manufacture of a medicament for the treatment of a condition which requires modulation of a dopamine receptor.

10 8. Use of a compound of formula (I) according to claim 7 wherein the condition is schizophrenia or substance abuse.

9. A method of treating a condition which requires modulation of dopamine receptors which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) according to claim 1 or claim 2.

15 10. A method of treating a condition according to claim 9 wherein the condition is schizophrenia or substance abuse.